August 28, 2020
Dutch Healthcare Authority published the decision for new medicines under add-on category in August 2020
In the Netherlands, the cost of medicine is an integral part of a DRG (DBC in Dutch). If the average price of a medication is more than €1000 per patient per year, a medicine can receive an add-on status, determined by the Dutch Healthcare Authority (NZa) and be reimbursed in addition to DRG. Medications that receive an add-on status are added to the G-Standard per ZI number. The G-Standaard specifies for which medicines an add-on service category has been established and NZa maximum tariffs for those medicines.

Since January 2017, healthcare providers register add-on medicines and coagulation factors based on brand name and strength instead of substance name, a form of administration, and indication. The NZa publishes its decisions about add-on medicines and coagulation factors via tariff decisions on the NZa website and in the Government Gazette on a monthly basis. The NZa updates the tariffs for add-on medicines annually.

In August 2020, 24 medicines received add-on status with defined maximum tariffs:

  • Alecensa (ZI number 16938763 with a tariff of €5,995.72)
  • Azacitidine (16932978 with a tariff of €376.64)
  • Caspofungin (16877853 with a tariff of €326.87, 16877861 with a tariff of €416.38)
  • Cyramza (16938801 with a tariff of €564.95, 16938828 with a tariff of €2,824.79)
  • Endoxan (16934822 with a tariff of €34.79)
  • Gazyvaro (16938836 with a tariff of €4,022.75)
  • Gemcitabine (16849515 with a tariff of €20.17, 16933745 with a tariff of €99.74)
  • Imbruvica (16879155 with a tariff of €1,924.37, 16879198 with a tariff of €3,848.75, 16879244 with a tariff of €5,773.13, 16879252 with a tariff of €7,697.51)
  • Imfinzi (16938852 with a tariff of €2,537.51, 16938860 with a tariff of €608.99)
  • Irinotecan (16933966 with a tariff of €430.55, 16933974 with a tariff of €719.40)
  • Kadcyla (16938879 with a tariff of €1,918.39, 16938887 with a tariff of €3,069.43)
  • Kisqali (16935217 with a tariff of €2,604.99 )
  • Lucentis (16938895 with a tariff of €806.45)
  • Lynparza (16931513 with a tariff of €5,448.03)
  • Mvasi (16936574 with a tariff of €1,348.81, 16936558 with a tariff of €337.20)
  • Ocrevus (16938909 with a tariff of €6,037.36)
  • Perjeta (16938925 with a tariff of €2,572.39)
  • Simponi (16938933 with a tariff of €1,125.84)
  • Tagrisso (16938941 with a tariff of €6,648.99, 16938968 with a tariff of €6,648.99)
  • Topotecan (16936825 with a tariff of €260.51)
  • Venclyxto (16938976 with a tariff of €6,320.44)
  • Voriconazole (16937279 with a tariff of €103.55)
  • Zejula (16938984 with a tariff of €10,083.67)
  • Zelboraf (16938992 with a tariff of €1,910.42)

The full details can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Close
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)